<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824689/" ref="ordinalpos=2436&amp;ncbi_uid=5464493&amp;link_uid=PMC3824689" image-link="/pmc/articles/PMC3824689/figure/fig3/" class="imagepopup">Figure 3.  From: IBP-mediated suppression of autophagy promotes growth and metastasis of breast cancer cells via activating mTORC2/Akt/FOXO3a <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>. </a></div><br /><div class="p4l_captionBody">IBP-mediated inhibition of autophagy is dependent on the mTORC2 signaling pathway in breast cancer cells. (<b>a</b> and <b>b</b>) MDA-MB-231 and MDA-MB-468 cells with different levels of IBP were treated without or with LY294002 (25 μm), rapamycin (10nm), OSI-027 (10 μm). Immunoblotting detected the levels of autophagy. (<b>c</b> and <b>d</b>) Cells were incubated with either rapamycin (10 nm) or OSI-027 (10 μm) or combined the two for 2 h. Immunoblotting detected the level of p-mTOR Ser2481, p-Akt Ser473, p-FOXO3a Thr32 and LC3-II</div></div>